Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ... Blood advances 4 (17), 4136-4146, 2020 | 91 | 2020 |
Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis T Robak, I Jarque, V Musteata, P Kiessling, U Massow, J Higginson, ... Blood 130, 15, 2017 | 16 | 2017 |
Targeted therapy of chronic myelogenous leukemia: experience of the Institute of Oncology of Moldova V Musteata, I Corcimaru Archives of the Balkan Medical Union 43 (3), 154-155, 2008 | 14 | 2008 |
GIPAP īn Republica Moldova: realizări şi perspective M Vasile, C Ion, S Mircea-Dumitru, M Larisa, R Maria, T Ludmila, C Maria, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 16 (2), 226-228, 2008 | 12 | 2008 |
A phase 2 study of MT-3724 to evaluate safety, pharmacodynamics and efficacy of MT-3724 for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma DO Persky, V Musteata, M Zodelava, T Perekhrestenko, AE Diaz, ... Blood 134, 5324, 2019 | 7 | 2019 |
Rozanolixizumab, an anti-FcRn antibody: final results from a phase II, multiple-dose study in patients with primary immune thrombocytopenia T Robak, M Kaźmierczak, I Jarque, V Musteata, J Trelinski, N Cooper, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 6 | 2019 |
Actualități īn managementul limfoamelor non-Hodgkin: profilul epidemiologic și socioeconomic V Musteață Общественное здоровье, экономика и менеджмент в медицине, 26-32, 2021 | 5 | 2021 |
S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY T Robak, M Kaźmierczak, I Jarque, V Musteata, J Treliński, N Cooper, ... HemaSphere 3, 379, 2019 | 5 | 2019 |
Treli nski T Robak, M Kazmierczak, I Jarque, V Musteata J, 0 | 5 | |
Clinico-laboratory pertinences and management of relapsed and refractory chronic myeloid leukemia V Musteata Journal of BUON 26 (3), 1165-1168, 2021 | 3 | 2021 |
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse … AE Diaz Duque, T Perekhrestenko, V Musteata, M Zodelava, TH Guthrie, ... Journal of Clinical Oncology 38 (15_suppl), TPS8074-TPS8074, 2020 | 3 | 2020 |
Manifestările clinice şi tratamentul limfoamelor Non-Hodgkin mediastinale la adulţi M Robu, I Corcimaru, L Musteaţă, M Popescu, V Gladīş, V Musteaţă, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 48 (3), 366-371, 2015 | 3 | 2015 |
Epidemiological and Disease Burden Profiles of Leukemias and Malignant Lymphomas: Overview and Trends in the Republic of Moldova and Worldwide V Musteata International Journal of Clinical Medicine 14 (2), 79-95, 2023 | 2 | 2023 |
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma PA Hamlin, V Musteata, SI Park, C Burnett, K Dabovic, T Strack, ... Cancer Research Communications 2 (5), 307-315, 2022 | 2 | 2022 |
Management of elderly patients with chronic myeloproliferative hemopathies V Musteaţă, V Stratan, L Catrinici, L Musteaţă, C Dudnic Moldovan Medical Journal 63 (6), 12-15, 2020 | 2 | 2020 |
Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) PA Hamlin, V Musteata, M Zodelava, SI Park, C Burnett, K Dabovic, ... Blood 134, 4098, 2019 | 2 | 2019 |
Rezultatele utilizării target-terapiei īn tratamentul combinat al tumorilor gastrointestinale stromale (GIST) M Cernat, N Ghidirim, I Mişin, L Antoci, A Donscaia, V Catrinici, ... Arta Medica 60 (3), 49-49, 2016 | 2 | 2016 |
Clinical patterns and complete blood count parameters in the young patients with primary myelofibrosis in the prefibrotic stage N Sghibneva-Bobeico, V Musteaţă, M Robu, L Jalbă, L Musteaţă, ... Revista de Ştiinţe ale Sănătăţii din Moldova 30 (4), 22-26, 2022 | 1 | 2022 |
Epidemiology and risk factors of warm and cold autoimmune hemolytic anemia M Vasile, TA Khan EDITOR COORDINATOR, 225, 2021 | 1 | 2021 |
Aspectele clinice și rezultatele tratamentului leucemiei limfocitare cronice. V Tomacinschii, M Robu, I Corcimaru, V Musteaţă, L Musteaţă, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 59 (2-3), 61-65, 2018 | 1 | 2018 |